Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_assertion type Assertion NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_head.
- NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_assertion description "[Resistance to camptothecin (CPT), a topoisomerase I (Top1) inhibitor, is frequently encountered in non-small cell lung cancer (NSCLC) and CPT resistance is linked with TDP1, an enzyme capable of cleaving the covalent linkage between stabilized Top1 with DNA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_provenance.
- NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_assertion evidence source_evidence_literature NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_provenance.
- NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_assertion SIO_000772 17118488 NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_provenance.
- NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_assertion wasDerivedFrom befree-20140225 NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_provenance.
- NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_assertion wasGeneratedBy ECO_0000203 NP924510.RA0fOUssiXu2xEAnpv_PIF4k0TkkQkI-v_2Hud3sFIK70130_provenance.